Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Flaminia Russo
Institutions:
Azienda Ospedaliera Sant'Andrea,
Sapienza University of Rome
Observed institutions:
Federico II University Hospital,
Azienda Ospedaliera Sant'Andrea,
University of Naples Federico II,
Sapienza University of Rome
ORCID:
0000-0003-4703-4358
Observed ORCID:
0000-0003-4703-4358
OpenAlex ID:
A5062782255
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
2024
·
Roberta Modica
, Anna La Salvia
, et al.
·
Endocrine
·
14
PDF
Glucagonoma and Glucagonoma Syndrome: An Updated Review
2025
·
Sofia Anelli
, Rossella Mazzilli
, et al.
·
Clinical Endocrinology
·
10
PDF
Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group
2024
·
Giovanni Vitale
, Germano Gaudenzi
, et al.
·
Reviews in Endocrine and Metabolic Disorders
·
10
Short fasting test as a reliable and effective tool to diagnose insulinoma
2024
·
Nevena Mikovic
, Rossella Mazzilli
, et al.
·
Endocrine
·
6
PDF
Pathophysiology and treatment of exercise-associated hyponatremia
2025
·
Barbara Altieri
, Irene Aini
, et al.
·
Journal of Endocrinological Investigation
·
5
PDF
Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions
2025
·
Rosaria M. Ruggeri
, Erika Maria Grossrubatscher
, et al.
·
Reviews in Endocrine and Metabolic Disorders
·
5
PDF
Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors
2024
·
Antongiulio Faggiano
, Flaminia Russo
, et al.
·
Journal of Neuroendocrinology
·
5
PDF
Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?
2023
·
Giuseppe Fanciulli
, Roberta Modica
, et al.
·
Frontiers in Endocrinology
·
5
PDF
Neuroendocrine tumors and diabetes mellitus: which treatment and which effect
2025
·
Rossella Mazzilli
, Virginia Zamponi
, et al.
·
Endocrine
·
4
Clinical Factors Predicting Multiple Endocrine Neoplasia Type 1 and Type 4 in Patients with Neuroendocrine Tumors
2023
·
Antongiulio Faggiano
, Beatrice Fazzalari
, et al.
·
Genes
·
3
PDF
The impact of pharmacological treatments on oxidative stress, inflammatory parameters and semen characteristics
2023
·
Virginia Zamponi
, Rossella Mazzilli
, et al.
·
Endocrine Abstracts
·
1
Short fasting test as reliable and effective tool to diagnose insulinoma
2022
·
Nevena Mikovic
, Virginia Zamponi
, et al.
·
Endocrine Abstracts
·
1
EP1224 - ECE_3614 - Everolimus in lung neuroendocrine tumors: statin-associated myopathy risk and potential PFS benefit of concomitant lipid-lowering therapy
2026
·
Maurizio Martiradonna
, Flaminia Russo
, et al.
·
European Journal of Endocrinology
PDF
Statins Support the Antitumor Activity of Somatostatin Analogues in Advanced Bronchopulmonary Neuroendocrine Tumors: A Clinical and In Vitro Study
2026
·
Giulia Pecora
, Camilla Mancini
, et al.
·
Lipidology
PDF
Anti-Ma2 Paraneoplastic Encephalitis and Testicular Cancer: When the Hypothalamus Whispers—A Case Report and Systematic Review with Emphasis on Hypothalamic-Endocrine Dysfunction
2026
·
Virginia Zamponi
, Piero Paravani
, et al.
·
Medical Sciences
PDF
Gestione del diabete nei pazienti con tumore neuroendocrino tra nuovi e “vecchi” farmaci
2025
·
Rosaria M. Ruggeri
, Erika Maria Grossrubatscher
, et al.
·
L Endocrinologo
Author response for "Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors"
2024
·
Antongiulio Faggiano
, Flaminia Russo
, et al.
·
Publons reviews and discussion
Endocrine-metabolic disorders in patients with gastroenteropancreatic and lung neuroendocrine tumors
2022
·
Virginia Zamponi
, Rossella Mazzilli
, et al.
·
Endocrine Abstracts
Show more works
View as search
Works count:
18
Citation count:
69
H-index:
5
I10-index:
3
Year
Topic
Type